Colorado lawmakers tap reserve, end tax breaks to fill budget gap
State of play: The legislation will generate fierce debate about how the state should manage its money when lawmakers return Thursday for a special legislative session.
The core of the Democratic plan eliminates a handful of corporate tax breaks worth a combined $300 million to $400 million.
The five-bill package will limit the business tax deduction, remove corporate tax breaks on foreign-sold goods and crack down on corporate profit shifting to tax haven countries.
The intrigue: The most controversial proposal is lowering the state's 15% financial reserve by $200 million to $300 million, dropping it to 13% at a time when fiscal analysts are warning about a potential recession.
Yes, but: Those moves are not enough to close a roughly $750 million gap.
Instead, lawmakers will punt $300 million in spending cuts to balance the $44 billion state budget to the governor in consultation with the legislative Joint Budget Committee in the coming weeks.
The governor is expected to move quickly to implement cuts by Sept. 1.
What they're saying: "We're looking forward to rolling up our sleeves and making sure we can maintain strong fiscal stewardship here in Colorado," Gov. Jared Polis told Axios Denver in a recent interview.
Between the lines: More than most states, Colorado is susceptible to changes in federal taxes because they affect state income taxes. The federal tax bill, known as H.R. 1, reduced the state's individual and corporate income taxes by an estimated $1.2 billion, according to the governor's office.
The other side: Republican state lawmakers are touting the cuts from Trump's tax bill and pushing back against Democratic efforts to generate new tax revenue, suggesting spending cuts are what is most needed.
Sen. Byron Pelton (R-Sterling) plans to introduce legislation requiring voter approval for any bill that changes state tax liability caused by federal tax law.
What's next: Beyond the budget, Democratic lawmakers also plan to introduce legislation to stabilize the state's health care marketplaces amid projections that thousands of residents could lose their insurance and enable Planned Parenthood to accept Medicaid payments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Medtronic PLC (MDT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance
This article first appeared on GuruFocus. Revenue: $8.6 billion, grew 8.4% reported and 4.8% organic. Cardiovascular Growth: 7% growth, driven by nearly 50% growth in cardiac ablation solutions. Neuroscience Growth: 3% growth, with mid-single-digit growth in cranial and spinal technologies. Medsurge Growth: 2% growth, with high single-digit growth in advanced energy. Diabetes Growth: 8% growth, including 11% growth in international markets. Adjusted Gross Margin: 65.1%, down 80 basis points year over year. Adjusted Operating Margin: 23.6%. Adjusted EPS: $1.26, $0.03 above the midpoint of guidance. R&D Investment: Up 7.7%, 100 basis points ahead of revenue growth. Fiscal Year '26 Organic Revenue Growth Guidance: Approximately 5%. Fiscal Year '26 EPS Guidance: Raised to $5.60 to $5.66. Warning! GuruFocus has detected 7 Warning Signs with ODFJF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Medtronic PLC (NYSE:MDT) reported consistent mid-single-digit revenue growth, with EPS exceeding guidance. The cardiovascular segment showed strong performance, with nearly 50% growth in cardiac ablation solutions driven by innovative product rollouts. The company raised its EPS guidance for the full year, reflecting confidence in continued financial acceleration. Medtronic PLC (NYSE:MDT) is poised for growth in the second half of the fiscal year, with several product launches and market expansions planned. The planned separation of the diabetes business is expected to be EPS accretive and improve operating margins, enhancing shareholder value. Negative Points Neuroscience growth was below trend due to specialty therapies, though improvements are expected in subsequent quarters. The Medsurge segment grew only 2%, aligning with expectations but indicating slower growth compared to other segments. The diabetes segment faced challenges in the US market, with growth primarily driven by international sales. Gross margin decreased by 80 basis points year-over-year, impacted by business mix and manufacturing ramp-up costs. Tariffs are expected to have a negative impact of approximately $185 million for fiscal '26, though this is an improvement from previous estimates. Q & A Highlights Q: Can you provide an update on the CAS business and its impact on overall growth? A: Geoff Martha, CEO, explained that the CAS business is accelerating, with 72% growth in the US. The company is confident in its ability to accelerate growth over FY26, with new technologies and a strong pipeline expected to have an outsized impact on US growth. Thierry Pieton, CFO, added that the US growth was impacted by slower growth in certain areas, but expects improvement as new products ramp up. Q: What is the purpose of the new Board committees focused on growth and operations? A: Geoff Martha, CEO, stated that the committees will provide focus and support management, particularly in growth and operational performance. The committees will include new directors with deep medtech experience and will have more frequent interactions with management to drive focus and execution. Q: Is the $2 billion target for annual CAS sales achievable in fiscal '26? A: Geoff Martha, CEO, confirmed that the target of an additional $1 billion on top of the FY25 base is on track. While it might extend into FY27, the company is confident in achieving this near-term goal. Q: How will the new directors and committees impact capital allocation and EPS growth? A: Geoff Martha, CEO, emphasized that the company is entering a new chapter focused on value creation. This includes more M&A, portfolio optimization, and increased investment in growth drivers. The committees will help ensure these strategies are executed effectively. Q: Can you discuss the potential impact of renal denervation on Medtronic's growth profile? A: Geoff Martha, CEO, highlighted that renal denervation (RDN) is a significant growth opportunity, with a massive patient population. The company is investing in market development and expects RDN to be a major driver of growth, potentially becoming one of the largest product categories for Medtronic. Q: What is the status of the diabetes business separation and its impact on growth? A: Thierry Pieton, CFO, confirmed that the separation is on track, with completion expected within 15 months. The diabetes business is entering a strong innovation cycle, and the separation is expected to be a value-creating event for shareholders. Q: How is the Hugo robotic system performing in international markets, and what are the expectations for the US launch? A: Michael Marinaro, EVP, stated that Hugo is performing well in over 30 countries, with significant double-digit growth in current accounts. The system's modular design and partnership approach are key strengths. The company is preparing for the US launch, with FDA approval processes underway. Q: What are the growth prospects for Medtronic's slower-growing businesses? A: Geoff Martha, CEO, noted that several slower-growing businesses have specific growth accelerators, such as new products and market expansions. The company is focused on driving growth across all segments, with organic and inorganic strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
'South Park' Turns Up The Heat On Trump With 'Perfect' Return Of Beloved Character
'South Park' released a new clip teasing Wednesday night's episode that features the return of a fan-favorite character as the show appears set to continue trolling President Donald Trump. The clip shows Towelie ― a sentient towel who loves to get high ― arriving by bus in Washington, D.C. to find the city under military control. 'This seems like the perfect place for a towel,' Towelie says as he watches a tank roll past the White House ― mimicking the real-life situation in which Trump has sent the National Guard into the city. Trump has claimed the military is needed to bring order to a city besieged by crime. However, the violent crime rate there dropped in both 2024 and 2025, leading critics to blast the move as a 'stunt.' 'South Park' has pulled a few stunts of its own since the show returned last month, mocking corporate parent Paramount for caving to Trump by agreeing to pay $16 million to settle a lawsuit over '60 Minutes' that most legal observers considered frivolous. Related: Trump has claimed the settlement includes PSAs, and 'South Park' mockingly gave him one at the end of the episode, which showed a very realistic Trump stripping in the desert until he was naked, complete with a talking 'teeny tiny' penis. The show continued to go after Trump and his administration in the second episode, which focused mostly on Homeland Security Secretary Kristi Noem. The next episode airs Wednesday night on Comedy Central, and will stream on Paramount+. 'South Park' Goes Scorched-Earth On Trump In Shockingly NSFW Season Premiere Aubrey Plaza Details 'Awfulness' After Her Husband's Shocking Death Elon Musk Was Not Pleased With 'Silicon Valley' Show's Portrayal Of Tech Parties
USA Today
24 minutes ago
- USA Today
Guns or weed? Trump administration says you can't use both.
The Justice Department wants the Supreme Court to make clear that regular pot smokers, and other users of illegal drugs, cannot own guns. WASHINGTON – The Trump administration's aggressive defense of gun rights has at least one exception. The government's lawyers want the Supreme Court to make clear that regular pot smokers – and other drug users − shouldn't be allowed to own firearms. An appeals court has said a federal law making it a crime for drug users to have a gun can't be used against someone based solely on their past drug use. Limiting the law to blocking the use of guns while a person is high effectively guts the statute that reduces gun violence, the Justice Department told the Supreme Court. They're asking the justices to overturn the appeals court's decision. Trump's Justice Department has sided with gun owners in other cases The department's defense of the law is particularly notable as the Trump administration has sided with gun rights advocates in other cases – including one in which they declined to appeal a lower court's ruling against a federal law setting 21 as the minimum age to own a handgun. More: Trump DOJ wants Supreme Court to bring down hammer on gun rules But on the issue of drug use, the government is appealing four cases to the Supreme Court, asking the justices to focus on one involving a dual citizen of the United States and Pakistan who was charged with unlawfully owning a Glock pistol because he regularly smoked marijuana. The FBI had been monitoring Ali Danial Hemani because of his alleged connection to Iran's paramilitary Revolutionary Guard, which the government has designated a global terrorist group, according to filings. The government also alleges Hemani used and sold promethazine, an antihistamine used to treat allergies and motion sickness that can boost an opioid high, and used cocaine, although he was prosecuted based on his marijuana use. Hemani's attorneys said the government is trying to 'inflame and disparage' Hemani's character and the only facts that matter are that he was not high when the FBI found the Glock 19 in his Texas home. Hemani was charged with violating the federal law that prohibits the possession of firearms by a person who 'is an unlawful user of or addicted to any controlled substance.' More: Supreme Court sides with Biden and upholds regulations of ghost guns to make them traceable Appeals court ruled past drug use not enough to stop gun ownership The New Orleans-based 5th U.S. Circuit Court of Appeals said that the law can't be applied to Hamani under the Supreme Court's landmark 2022 decision that gun prohibitions must be grounded in history that is "consistent with our tradition of gun regulation." While history and tradition support 'some limits on a presently intoxicated person's right to carry a weapon,' the appeals court said, 'they do not support disarming a sober person based solely on past substance usage.' The Justice Department said the appeals court got it wrong. Laws that existed at the time the country was founded restricted the rights of habitual drinkers, even when they were sober, they argued. 'And for about as long as legislatures have regulated drugs, they have prohibited the possession of arms by drug users and addicts – not just by persons under the influence of drugs,' they wrote. Law used in hundreds of prosecutions, including Hunter Biden's Since the federal government created its background-check system for firearms in 1998, the federal restriction on drug users has stopped more gun sales than any requirement other than the ban on felons and fugitives owning weapons, according to the filing. And it's used in hundreds of prosecutions each year, they said. (Hunter Biden, who was later pardoned by his father during President Joe Biden's final weeks in office, was convicted in 2024 of violating the law by purchasing a gun despite having a known drug addiction.) Hunter Biden trial recap Joe Biden's son guilty on all charges in historic gun case Hemani's lawyers argue that the government's interpretation of the law makes no sense when an estimated 19% of Americans have used marijuana and about 32% own a firearm. That means millions of Americans are violating the law that could put them behind bars for up to 15 years, they said in a filing. The appeals court, Hemani's lawyers said, correctly applied the Supreme Court's past decisions and 'common sense' to rule that 'history and tradition only supports a ban on carrying firearms while intoxicated.' In addition to the 5th U.S. Circuit Court of Appeals, two other appeals courts have issued rulings that restrict use of the federal ban: both courts ruled there should be individualized assessments of defendants' drug use to determine if their rights could be restricted. Trump administration touts program to restore gun rights The Justice Department argues that 'marginal' cases are better addressed on a case-by-case basis, through a federal program the Trump administration restarted that lets individuals petition to have their gun rights restored. The administration's championship of that program makes it less surprising that the Justice Department is vigorously defending the ban on drug users having guns, said Andrew Willinger, executive director of the Duke Center for Firearms Law, a research center. In addition, the administration has shown a broad desire to crack down on illegal drug use. 'In some sense, when those two areas are colliding – gun rights and anti-drug policies – it looks like anti-drug policies are going to win out,' he said. More: Supreme Court rules Mexico can't sue US gunmakers over cartel violence Willinger said there's a relatively strong chance the Supreme Court will get involved, which the justices tend to do when a lower court strikes down or restricts the application of a federal criminal law – especially if the government asks them to intervene. But the high court could also wait to see how other appeals courts handle similar cases and how well the Justice Department's program for restoring gun rights addresses these concerns, he said. The court could announce whether it will take up the issue this fall.
